A small pediatric trial reported better sedation and pain-related ratings with the combination than with midazolam alone. Numerical and methodological limitations constrain its broader claims.
The comparison
Mahmoudi Nesheli described forty children undergoing a first diagnostic bone-marrow procedure. The randomized comparison involved oral midazolam alone or oral midazolam with ketamine, with behavior assessed using a structured comfort measure.
The reported overall comparison favored the combination. This was a procedure-specific assessment, rather than a demonstration that midazolam alone provides the same analgesia as a regimen containing ketamine.
Read the numerical reporting carefully
The abstract’s age-group counts add to forty-one despite the stated sample of forty, and a reported age-related comparison had p=0.22. That latter value does not demonstrate a statistically significant age effect. A p-value printed as 0.00 also should not be interpreted as literally zero probability.
The authors described restrictions in enrollment, procedure delivery, blinding, and questionnaire completion. The small study cannot settle rare-event safety or establish a protocol for all children undergoing invasive procedures.
Application to testimony
Distinguish pain behavior from sedation and memory. A favorable combined rating cannot show that every patient had adequate analgesia or that no respiratory risk existed. The paper is a limited comparative observation to be interpreted with its actual population, assessment tool, and reporting imperfections.
Source
Original analysis of the supplied paper: Comparison Effect of Midazolam Alone and Midazolam Combined with Ketamine in Bone Marrow Aspiration. Paper identifier: PMC4688596.
Leave a Reply